Suggested guidelines for the diagnosis and management of urea cycle disorders

Orphanet Journal of Rare Diseases

Carlo Dionisi-Vici³  Vicente Rubio⁷  Martin Lindner^1,14  Vassili Valayannopoulos¹  Aude Servais⁸  René Santer²  Pablo Sanjurjo Crespo⁴  Diego Martinelli³  Daniela Karall⁵  Martina Huemer^1,11  Marjorie Dixon^1,13  Anupam Chakrapani⁹  Alberto Burlina^1,12  Nathalie Boddaert^1,10  Johannes Häberle⁶ 

[1] Reference Center for Inherited Metabolic Disorders (MaMEA), Hopital Necker-Enfants Malades, 149 Rue de Sevres, Paris, 75015, France;Universitätsklinikum Hamburg Eppendorf, Klinik für Kinder- und Jugendmedizin, Martinistr. 52, Hamburg, 20246, Germany;Division of Metabolism, Bambino Gesù Children’s Hospital, IRCCS, Piazza S. Onofrio 4, Rome, I-00165, Italy;Division of Pediatric Metabolism, Cruces Children Hospital, Baracaldo, 48903, Spain;University Children’s Hospital, Medical University Innsbruck, Anichstrasse 35, Innsbruck, 6020, Austria;University Children’s Hospital Zurich and Children’s Research Centre, Zurich, 8032, Switzerland;Instituto de Biomedicina de Valencia del Consejo Superior de Investigaciones Científicas (IBV-CSIC) and Centro de Investigación Biomédica en Red para Enfermedades Raras (CIBERER), C/ Jaume Roig 11, Valencia, 46010, Spain;Service de Néphrologie et maladies métaboliques adulte Hôpital Necker 149, rue de Sèvres, Paris, 75015, France;Birmingham Children’s Hospital NHS Foundation Trust, Steelhouse Lane, Birmingham, B4 6NH, United Kingdom;Radiologie Hopital Necker, Service Radiologie Pediatrique, 149 Rue De Sevres, Paris 15, 75015, France;Kinderabteilung, LKH Bregenz, Carl-Pedenz-Strasse 2, Bregenz, A-6900, Austria;Department of Pediatrics, Division of Inborn Metabolic Disease, University Hospital Padua, Via Giustiniani 3, Padova, 35128, Italy;Dietetic Department, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, WC1N 3JH, United Kingdom;University Children’s Hospital, Im Neuenheimer Feld 430, Heidelberg, 69120, Germany

关键词: Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome;    Arginase 1;    Argininosuccinate lyase;    Argininosuccinate synthetase;    Ornithine carbamoyl transferase;    Ornithine transcarbamylase;    Carbamoylphosphate synthetase 1;    N-acetylglutamate synthase;    Hyperammonemia;    UCD;    Urea cycle disorders;   

Others  :  864374
DOI  :  10.1186/1750-1172-7-32

 received in 2011-11-24, accepted in 2012-04-06,  发布年份 2012

【 摘 要 】

Urea cycle disorders (UCDs) are inborn errors of ammonia detoxification/arginine synthesis due to defects affecting the catalysts of the Krebs-Henseleit cycle (five core enzymes, one activating enzyme and one mitochondrial ornithine/citrulline antiporter) with an estimated incidence of 1:8.000. Patients present with hyperammonemia either shortly after birth (~50%) or, later at any age, leading to death or to severe neurological handicap in many survivors. Despite the existence of effective therapy with alternative pathway therapy and liver transplantation, outcomes remain poor. This may be related to underrecognition and delayed diagnosis due to the nonspecific clinical presentation and insufficient awareness of health care professionals because of disease rarity. These guidelines aim at providing a trans-European consensus to: guide practitioners, set standards of care and help awareness campaigns. To achieve these goals, the guidelines were developed using a Delphi methodology, by having professionals on UCDs across seven European countries to gather all the existing evidence, score it according to the SIGN evidence level system and draw a series of statements supported by an associated level of evidence. The guidelines were revised by external specialist consultants, unrelated authorities in the field of UCDs and practicing pediatricians in training. Although the evidence degree did hardly ever exceed level C (evidence from non-analytical studies like case reports and series), it was sufficient to guide practice on both acute and chronic presentations, address diagnosis, management, monitoring, outcomes, and psychosocial and ethical issues. Also, it identified knowledge voids that must be filled by future research. We believe these guidelines will help to: harmonise practice, set common standards and spread good practices with a positive impact on the outcomes of UCD patients.

【 授权许可】

   
2012 Häberle et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Brusilow SW, Maestri NE: Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr 1996, 43:127-170.
• [2]Dionisi-Vici C, Rizzo C, Burlina AB, Caruso U, Sabetta G, Uziel G, Abeni D: Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey. J Pediatr 2002, 140:321-327.
• [3]Wilcken B: Problems in the management of urea cycle disorders. Mol Genet Metab 2004, 81(Suppl 1):S86-S91.
• [4]Bachmann C: Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. Eur J Pediatr 2003, 162:410-416.
• [5]Nassogne MC, Heron B, Touati G, Rabier D, Saudubray JM: Urea cycle defects: management and outcome. J Inherit Metab Dis 2005, 28:407-414.
• [6]Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED: Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies. N Engl J Med 1984, 310:1500-1505.
• [7]Maestri NE, Clissold D, Brusilow SW: Neonatal onset ornithine transcarbamylase deficiency: a retrospective analysis. J Pediatr 1999, 134:268-272.
• [8]Harada E, Nishiyori A, Tokunaga Y, Watanabe Y, Kuriya N, Kumashiro R, Kuno T, Kuromaru R, Hirose S, Ichikawa K, Yoshino M: Late-onset ornithine transcarbamylase deficiency in male patients: prognostic factors and characteristics of plasma amino acid profile. Pediatr Int 2006, 48:105-111.
• [9]Uchino T, Endo F, Matsuda I: Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J Inherit Metab Dis 1998, 21(Suppl 1):151-159.
• [10]Nicolaides P, Liebsch D, Dale N, Leonard J, Surtees R: Neurological outcome of patients with ornithine carbamoyltransferase deficiency. Arch Dis Child 2002, 86:54-56.
• [11]Enns GM: Neurologic damage and neurocognitive dysfunction in urea cycle disorders. Semin Pediatr Neurol 2008, 15:132-139.
• [12]Brusilow S, Horwich A: Urea cycle enzymes. In The metabolic & molecular bases of inherited disease. 8th edition. Edited by Scriver C, Beaudet A, Sly W, Valle D. McGraw-Hill, New York; 2001:1909-1963.
• [13]Gropman AL, Summar M, Leonard JV: Neurological implications of urea cycle disorders. J Inherit Metab Dis 2007, 30:865-879.
• [14]Burlina AB, Ogier H, Korall H, Trefz FK: Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients. Mol Genet Metab 2001, 72:351-355.
• [15]Trevisson E, Salviati L, Baldoin MC, Toldo I, Casarin A, Sacconi S, Cesaro L, Basso G, Burlina AB: Argininosuccinate lyase deficiency: mutational spectrum in Italian patients and identification of a novel ASL pseudogene. Hum Mutat 2007, 28:694-702.
• [16]Leonard JV, Morris AA: Urea cycle disorders. Semin Neonatol 2002, 7:27-35.
• [17]Smith W, Kishnani PS, Lee B, Singh RH, Rhead WJ, Sniderman King L, Smith M, Summar M: Urea cycle disorders: clinical presentation outside the newborn period. Crit Care Clin 2005, 21:S9-S17.
• [18]Kvedar JC, Baden HP, Baden LA, Shih VE, Kolodny EH: Dietary management reverses grooving and abnormal polarization of hair shafts in argininosuccinase deficiency. Am J Med Genet 1991, 40:211-213.
• [19]Patel HP, Unis ME: Pili torti in association with citrullinemia. J Am Acad Dermatol 1985, 12:203-206.
• [20]Cowley DM, Bowling FG, McGill JJ, van Dongen J, Morris D: Adult-onset arginase deficiency. J Inherit Metab Dis 1998, 21:677-678.
• [21]Crombez EA, Cederbaum SD: Hyperargininemia due to liver arginase deficiency. Mol Genet Metab 2005, 84:243-251.
• [22]Salvi S, Santorelli FM, Bertini E, Boldrini R, Meli C, Donati A, Burlina AB, Rizzo C, Di Capua M, Fariello G, Dionisi-Vici C: Clinical and molecular findings in hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. Neurology 2001, 57:911-914.
• [23]Häberle J, Vilaseca MA, Meli C, Rigoldi M, Jara F, Vecchio I, Capra C, Parini R: First manifestation of citrullinemia type I as differential diagnosis to postpartum psychosis in the puerperal period. Eur J Obstet Gynecol Reprod Biol 2010, 149:228-229.
• [24]Wong LJ, Craigen WJ, O’Brien WE: Postpartum coma and death due to carbamoyl-phosphate synthetase I deficiency. Ann Intern Med 1994, 120:216-217.
• [25]Arn PH, Hauser ER, Thomas GH, Herman G, Hess D, Brusilow SW: Hyperammonemia in women with a mutation at the ornithine carbamoyltransferase locus. A cause of postpartum coma. N Engl J Med 1990, 322:1652-1655.
• [26]Gyato K, Wray J, Huang ZJ, Yudkoff M, Batshaw ML: Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency. Ann Neurol 2004, 55:80-86.
• [27]Häberle J, Pauli S, Schmidt E, Schulze-Eilfing B, Berning C, Koch HG: Mild citrullinemia in Caucasians is an allelic variant of argininosuccinate synthetase deficiency (citrullinemia type 1). Mol Genet Metab 2003, 80:302-306.
• [28]Kurokawa K, Yorifuji T, Kawai M, Momoi T, Nagasaka H, Takayanagi M, Kobayashi K, Yoshino M, Kosho T, Adachi M, et al.: Molecular and clinical analyses of Japanese patients with carbamoylphosphate synthetase 1 (CPS1) deficiency. J Hum Genet 2007, 52:349-354.
• [29]Caldovic L, Morizono H, Panglao MG, Lopez GY, Shi D, Summar ML, Tuchman M: Late onset N-acetylglutamate synthase deficiency caused by hypomorphic alleles. Hum Mutat 2005, 25:293-298.
• [30]Ficicioglu C, Mandell R, Shih VE: Argininosuccinate lyase deficiency: longterm outcome of 13 patients detected by newborn screening. Mol Genet Metab 2009, 98:273-277.
• [31]Ahrens MJ, Berry SA, Whitley CB, Markowitz DJ, Plante RJ, Tuchman M: Clinical and biochemical heterogeneity in females of a large pedigree with ornithine transcarbamylase deficiency due to the R141Q mutation. Am J Med Genet 1996, 66:311-315.
• [32]Ausems MG, Bakker E, Berger R, Duran M, van Diggelen OP, Keulemans JL, de Valk HW, Kneppers AL, Dorland L, Eskes PF, et al.: Asymptomatic and late-onset ornithine transcarbamylase deficiency caused by a A208T mutation: clinical, biochemical and DNA analyses in a four-generation family. Am J Med Genet 1997, 68:236-239.
• [33]Klaus V, Vermeulen T, Minassian B, Israelian N, Engel K, Lund AM, Roebrock K, Christensen E, Häberle J: Highly variable clinical phenotype of carbamylphosphate synthetase 1 deficiency in one family: an effect of allelic variation in gene expression? Clin Genet 2009, 76:263-269.
• [34]Teufel U, Weitz J, Flechtenmacher C, Prietsch V, Schmidt J, Hoffmann GF, Kölker S, Engelmann G: High urgency liver transplantation in ornithine transcarbamylase deficiency presenting with acute liver failure. Pediatr Transplant 2011, 15:E110-E115.
• [35]Fecarotta S, Parenti G, Vajro P, Zuppaldi A, Della Casa R, Carbone MT, Correra A, Torre G, Riva S, Dionisi-Vici C, et al.: HHH syndrome (hyperornithinaemia, hyperammonaemia, homocitrullinuria), with fulminant hepatitis-like presentation. J Inherit Metab Dis 2006, 29:186-189.
• [36]Ito S, Kurasawa G, Yamamoto K, Furuta I, Ishihara F, Kobayashi K, Saheki T, Matsuura T, Yamauchi M, Kakinoki H: A pregnant patient with fulminant hepatic failure was found to carry a novel missense mutation in the argininosuccinate synthetase gene. J Gastroenterol 2004, 39:1115-1117.
• [37]Mhanni AA, Chan A, Collison M, Seifert B, Lehotay DC, Sokoro A, Huynh HQ, Greenberg CR: Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (HHH) presenting with acute fulminant hepatic failure. J Pediatr Gastroenterol Nutr 2008, 46:312-315.
• [38]Faghfoury H, Baruteau J, de Baulny Ogier H, Häberle J, Schulze A: Transient fulminant liver failure as an initial presentation in citrullinemia type I. Mol Genet Metab 2011, 102:413-417.
• [39]de Groot MJ, Cuppen M, Eling M, Verheijen FW, Rings EH, Reijngoud DJ, de Vries MM, van Spronsen FJ: Metabolic investigations prevent liver transplantation in two young children with citrullinemia type I. J Inherit Metab Dis 2011.
• [40]Al-Hassnan ZN, Rashed MS, Al-Dirbashi OY, Patay Z, Rahbeeni Z, Abu-Amero KK: Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome with stroke-like imaging presentation: clinical, biochemical and molecular analysis. J Neurol Sci 2008, 264:187-194.
• [41]Choi JH, Kim H, Yoo HW: Two cases of citrullinaemia presenting with stroke. J Inherit Metab Dis 2006, 29:182-183.
• [42]Christodoulou J, Qureshi IA, McInnes RR, Clarke JT: Ornithine transcarbamylase deficiency presenting with strokelike episodes. J Pediatr 1993, 122:423-425.
• [43]Keegan CE, Martin DM, Quint DJ, Gorski JL: Acute extrapyramidal syndrome in mild ornithine transcarbamylase deficiency: metabolic stroke involving the caudate and putamen without metabolic decompensation. Eur J Pediatr 2003, 162:259-263.
• [44]Sperl W, Felber S, Skladal D, Wermuth B: Metabolic stroke in carbamyl phosphate synthetase deficiency. Neuropediatrics 1997, 28:229-234.
• [45]Wiltshire EJ, Poplawski NK, Harbord MG, Harrison RJ, Fletcher JM: Ornithine carbamoyltransferase deficiency presenting with chorea in a female. J Inherit Metab Dis 2000, 23:843-844.
• [46]Scheuerle AE, McVie R, Beaudet AL, Shapira SK: Arginase deficiency presenting as cerebral palsy. Pediatrics 1993, 91:995-996.
• [47]Singh RH, Rhead WJ, Smith W, Lee B, Sniderman King L, Summar Mz: Nutritional management of urea cycle disorders. Crit Care Clin 2005, 21:S27-S35.
• [48]Snebold NG, Rizzo JF, Lessell S, Pruett RC: Transient visual loss in ornithine transcarbamoylase deficiency. Am J Ophthalmol 1987, 104:407-412.
• [49]Anderson JM, Brodsky MC: Protracted cortical visual loss in a child with ornithine transcarbamylase deficiency. J Neuroophthalmol 2010, 30:99-101.
• [50]Kleijer WJ, Garritsen VH, Linnebank M, Mooyer P, Huijmans JG, Mustonen A, Simola KO, Arslan-Kirchner M, Battini R, Briones P, et al.: Clinical, enzymatic, and molecular genetic characterization of a biochemical variant type of argininosuccinic aciduria: prenatal and postnatal diagnosis in five unrelated families. J Inherit Metab Dis 2002, 25:399-410.
• [51]Pascual JC, Matarredona J, Mut J: Acrodermatitis enteropathica-like dermatosis associated with ornithine transcarbamylase deficiency. Pediatr Dermatol 2007, 24:394-396.
• [52]Gorker I, Tuzun U: Autistic-like findings associated with a urea cycle disorder in a 4-year-old girl. J Psychiatry Neurosci 2005, 30:133-135.
• [53]Serrano M, Perez-Duenas B, Gomez-Lopez L, Murgui E, Fons C, Garcıa-Cazorla A, Artuch R, Jara F, Arranz J, Häberle J, et al.: Neuropsychiatric manifestations in late-onset urea cycle disorder patients. J Child Neurol 2010, 25:352-358.
• [54]Sedel F, Baumann N, Turpin JC, Lyon-Caen O, Saudubray JM, Cohen D: Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis 2007, 30:631-641.
• [55]Häberle J: Clinical practice: the management of hyperammonemia. Eur J Pediatr 2011, 170:21-34.
• [56]Picca S, Dionisi-Vici C, Abeni D, Pastore A, Rizzo C, Orzalesi M, Sabetta G, Rizzoni G, Bartuli A: Extracorporeal dialysis in neonatal hyperammonemia: modalities and prognostic indicators. Pediatr Nephrol 2001, 16:862-867.
• [57]Bachmann C, Colombo JP: Acid–base status and plasma glutamine in patients with hereditary urea cycle disorders. In Advances in ammonia metabolism and hepatic encephalopathy. Edited by Soeters PB, Wilson JHP, Meijer AJ, Holm E. Elsevier, Amsterdam; 1988:72-78.
• [58]Marin-Valencia I, Vilaseca MA, Thio M, Garcia-Cazorla A, Artuch R, Campistol J: Assessment of the perimortem protocol in neonates for the diagnosis of inborn errors of metabolism. Eur J Paediatr Neurol 2010, 14:125-130.
• [59]Burton BK: Inborn errors of metabolism in infancy: a guide to diagnosis. Pediatrics 1998, 102:E69.
• [60]Leonard JV, Morris AA: Diagnosis and early management of inborn errors of metabolism presenting around the time of birth. Acta Paediatr 2006, 95:6-14.
• [61]Ellaway CJ, Wilcken B, Christodoulou J: Clinical approach to inborn errors of metabolism presenting in the newborn period. J Paediatr Child Health 2002, 38:511-517.
• [62]Saudubray JM, Sedel F, Walter JH: Clinical approach to treatable inborn metabolic diseases: an introduction. J Inherit Metab Dis 2006, 29:261-274.
• [63]Clay AS, Hainline BE: Hyperammonemia in the ICU. Chest 2007, 132:1368-1378.
• [64]Bachmann C: Inherited hyperammonemias. In Physician’s guide to the laboratory diagnosis of metabolic diseases. Edited by Blau N, Duran M, Blaskovic ME, Gibson KM. Springer, Berlin; 2003:261-276.
• [65]Hudak ML, Jones MD, Brusilow SW: Differentiation of transient hyperammonemia of the newborn and urea cycle enzyme defects by clinical presentation. J Pediatr 1985, 107:712-719.
• [66]Tuchman M, Georgieff MK: Transient hyperammonemia of the newborn: a vascular complication of prematurity? J Perinatol 1992, 12:234-236.
• [67]Ballard RA, Vinocur B, Reynolds JW, Wennberg RP, Merritt A, Sweetman L, Nyhan WL: Transient hyperammonemia of the preterm infant. N Engl J Med 1978, 299:920-925.
• [68]Summar ML, Barr F, Dawling S, Smith W, Lee B, Singh RH, Rhead WJ, Sniderman King L, Christman BW: Unmasked adult-onset urea cycle disorders in the critical care setting. Crit Care Clin 2005, 21:S1-S8.
• [69]Felig DM, Brusilow SW, Boyer JL: Hyperammonemic coma due to parenteral nutrition in a woman with heterozygous ornithine transcarbamylase deficiency. Gastroenterology 1995, 109:282-284.
• [70]Trivedi M, Zafar S, Spalding MJ, Jonnalagadda S: Ornithine transcarbamylase deficiency unmasked because of gastrointestinal bleeding. J Clin Gastroenterol 2001, 32:340-343.
• [71]Summar ML, Dobbelaere D, Brusilow S, Lee B: Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr 2008, 97:1420-1425.
• [72]Jensen V: The TURP syndrome. Can J Anaesth 1991, 38:90-96.
• [73]Ahrens M, Barsotti R, Batshaw M, Berry G, Cederbaum S, Jopling M, Lee B, LeMons C, Leonard JV, Markowitz D, et al.: Consensus statement from a conference for the management of patients with urea cycle disorders. In J Pediatr 2001, 138:S1-S5.
• [74]Summar M, Tuchman M: Proceedings of a consensus conference for the management of patients with urea cycle disorders. J Pediatr 2001, 138:S6-S10.
• [75]Summar M: Current strategies for the management of neonatal urea cycle disorders. J Pediatr 2001, 138:S30-S39.
• [76]Tomlinson S, Westall RG: Argininosuccinic Aciduria. Argininosuccinase and Arginase in Human Blood Cells. Clin Sci 1964, 26:261-269.
• [77]Yamaguchi S, Brailey LL, Morizono H, Bale AE, Tuchman M: Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene. Hum Mutat 2006, 27:626-632.
• [78]Gao HZ, Kobayashi K, Tabata A, Tsuge H, Iijima M, Yasuda T, Kalkanoglu HS, Dursun A, Tokatli A, Coskun T, et al.: Identification of 16 novel mutations in the argininosuccinate synthetase gene and genotype-phenotype correlation in 38 classical citrullinemia patients. Hum Mutat 2003, 22:24-34.
• [79]Rapp B, Häberle J, Linnebank M, Wermuth B, Marquardt T, Harms E, Koch HG: Genetic analysis of carbamoylphosphate synthetase I and ornithine transcarbamylase deficiency using fibroblasts. Eur J Pediatr 2001, 160:283-287.
• [80]Häberle J, Shchelochkov OA, Wang J, Katsonis P, Hall L, Reiss S, Eeds A, Willis A, Yadav M, Summar S, et al.: Molecular defects in human carbamoyl phosphate synthetase I: mutational spectrum, diagnostic and protein structure considerations. Hum Mutat 2011, 32:579-589.
• [81]Engel K, Nuoffer JM, Muhlhausen C, Klaus V, Largiader CR, Tsiakas K, Santer R, Wermuth B, Häberle J: Analysis of mRNA transcripts improves the success rate of molecular genetic testing in OTC deficiency. Mol Genet Metab 2008, 94:292-297.
• [82]Leonard JV, Ward Platt MP, Morris AA: Hypothesis: proposals for the management of a neonate at risk of hyperammonaemia due to a urea cycle disorder. Eur J Pediatr 2008, 167:305-309.
• [83]Maestri NE, Hauser ER, Bartholomew D, Brusilow SW: Prospective treatment of urea cycle disorders. J Pediatr 1991, 119:923-928.
• [84]Sniderman King L, Singh RH, Rhead WJ, Smith W, Lee B, Summar ML: Genetic counseling issues in urea cycle disorders. Crit Care Clin 2005, 21:S37-S44.
• [85]Häberle J, Koch HG: Genetic approach to prenatal diagnosis in urea cycle defects. Prenat Diagn 2004, 24:378-383.
• [86]Kamoun P, Fensom AH, Shin YS, Bakker E, Colombo JP, Munnich A, Bird S, Canini S, Huijmans JG, Chadefaux-Vekemans B, et al.: Prenatal diagnosis of the urea cycle diseases: a survey of the European cases. Am J Med Genet 1995, 55:247-250.
• [87]Chadefaux-Vekemans B, Rabier D, Chabli A, Blanc A, Aupetit J, Bardet J, Kamoun P: Improving the prenatal diagnosis of citrullinemia using citrulline/ornithine+arginine ratio in amniotic fluid. Prenat Diagn 2002, 22:456-458.
• [88]Mandell R, Packman S, Laframboise R, Golbus MS, Schmidt K, Workman L, Saudubray JM, Shih VE: Use of amniotic fluid amino acids in prenatal testing for argininosuccinic aciduria and citrullinaemia. Prenat Diagn 1996, 16:419-424.
• [89]Bachmann C: Long-term outcome of patients with urea cycle disorders and the question of neonatal screening. Eur J Pediatr 2003, 162(Suppl 1):S29-S33.
• [90]Wilcken B, Haas M, Joy P, Wiley V, Bowling F, Carpenter K, Christodoulou J, Cowley D, Ellaway C, Fletcher J, et al.: Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics 2009, 124:e241-e248.
• [91]Krivitzky L, Babikian T, Lee HS, Thomas NH, Burk-Paull KL, Batshaw ML: Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. Pediatr Res 2009, 66:96-101.
• [92]Cavicchi C, Malvagia S, la Marca G, Gasperini S, Donati MA, Zammarchi E, Guerrini R, Morrone A, Pasquini E: Hypocitrullinemia in expanded newborn screening by LC-MS/MS is not a reliable marker for ornithine transcarbamylase deficiency. J Pharm Biomed Anal 2009, 49:1292-1295.
• [93]Naylor EW, Chace DH: Automated tandem mass spectrometry for mass newborn screening for disorders in fatty acid, organic acid, and amino acid metabolism. J Child Neurol 1999, 14(Suppl 1):S4-S8.
• [94]Rashed MS: Clinical applications of tandem mass spectrometry: ten years of diagnosis and screening for inherited metabolic diseases. J Chromatogr B Biomed Sci Appl 2001, 758:27-48.
• [95]Sander J, Janzen N, Sander S, Steuerwald U, Das AM, Scholl S, Trefz FK, Koch HG, Haberle J, Korall H, et al.: Neonatal screening for citrullinaemia. Eur J Pediatr 2003, 162:417-420.
• [96]Mercimek-Mahmutoglu S, Moeslinger D, Häberle J, Engel K, Herle M, Strobl MW, Scheibenreiter S, Muehl A, Stockler-Ipsiroglu S: Long-term outcome of patients with argininosuccinate lyase deficiency diagnosed by newborn screening in Austria. Mol Genet Metab 2010, 100:24-28.
• [97]Sokoro AA, Lepage J, Antonishyn N, McDonald R, Rockman-Greenberg C, Irvine J, Lehotay DC: Diagnosis and high incidence of hyperornithinemia-hyperammonemia-homocitrullinemia (HHH) syndrome in northern Saskatchewan. J Inherit Metab Dis 2011.
• [98]Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A: Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med 2007, 356:2282-2292.
• [99]Schaefer F, Straube E, Oh J, Mehls O, Mayatepek E: Dialysis in neonates with inborn errors of metabolism. Nephrol Dial Transplant 1999, 14:910-918.
• [100]Feillet F, Leonard JV: Alternative pathway therapy for urea cycle disorders. J Inherit Metab Dis 1998, 21(Suppl 1):101-111.
• [101]Batshaw ML, MacArthur RB, Tuchman M: Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 2001, 138:S46-S54. discussion S54-45
• [102]Praphanphoj V, Boyadjiev SA, Waber LJ, Brusilow SW, Geraghty MT: Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonaemia. J Inherit Metab Dis 2000, 23:129-136.
• [103]Picca S, Bartuli A, Dionisi-Vici C: Medical management and dialysis therapy for the infant with an inborn error of metabolism. Semin Nephrol 2008, 28:477-480.
• [104]Sadowski RH, Harmon WE, Jabs K: Acute hemodialysis of infants weighing less than five kilograms. Kidney Int 1994, 45:903-906.
• [105]Hiroma T, Nakamura T, Tamura M, Kaneko T, Komiyama A: Continuous venovenous hemodiafiltration in neonatal onset hyperammonemia. Am J Perinatol 2002, 19:221-224.
• [106]Dixon M, In Clinical Pediatric Dietetics. Edited by Shaw, Lawson: Disorders of amino acid metabolism, organic acidemias and urea cycle defects. Organic acidemias and urea cycle disorders. In Edited by Acosta PB. 2007, 357-389.
• [107]Singh RH: Nutrition management of patients with inherited disorders of urea cycle enzymes. In Nutrition management of patients with inherited metabolic disorders. Edited by Acosta PB. Jones & Bartlett Learning, Sudbury; 2009:405-429.
• [108]Berry GT, Steiner RD: Long-term management of patients with urea cycle disorders. J Pediatr 2001, 138:S56-S60. discussion S60-51
• [109]Protein and amino acid requirement in human nutrition. In: WHO Technical Report Series:. Report of a joint WHO/FAO/UNU expert consultation Series 935 2007.
• [110]Leonard JV: The nutritional management of urea cycle disorders. J Pediatr 2001, 138:S40-S44. discussion S44-45
• [111]Adams S, Champion H, Dawson S, Daly A, Dixon M, Dunlop C, Eardley J, Evans S, Ferguson C, Lowry S, et al.: Dietary management of urea cycle disorders: UK practice (abstract). J Inherit Metab Dis 2010, 33:S170.
• [112]Scaglia F, Carter S, O’Brien WE, Lee B: Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Mol Genet Metab 2004, 81(Suppl 1):S79-S85.
• [113]Scaglia F: New insights in nutritional management and amino acid supplementation in urea cycle disorders. Mol Genet Metab 2010, 100(Suppl 1):S72-S76.
• [114]Bachmann C: Hyperammonaemia: review of current treatment strategies. In Pathophysiology and management of hyperammonemia. Edited by Bachmann C, Häberle J, Leonard JV. SPS publications, Heilbronn; 2006:157-173.
• [115]Vlaardingerbroek H, Hornstra G, de Koning TJ, Smeitink JA, Bakker HD, de Klerk HB, Rubio-Gozalbo ME: Essential polyunsaturated fatty acids in plasma and erythrocytes of children with inborn errors of amino acid metabolism. Mol Genet Metab 2006, 88:159-165.
• [116]Sanjurjo P, Ruiz JI, Montejo M: Inborn errors of metabolism with a protein-restricted diet: effect on polyunsaturated fatty acids. J Inherit Metab Dis 1997, 20:783-789.
• [117]Dixon M, White F, Leonard J: Breast feeding in metabolic disease: how successful is this? Compilation of papers presented at the Fifth Dietitians Meeting at the VIII International Congress of Inborn Errors of Metabolism. Cambridge 2000, 4-8.
• [118]Huner G, Baykal T, Demir F, Demirkol M: Breastfeeding experience in inborn errors of metabolism other than phenylketonuria. J Inherit Metab Dis 2005, 28:457-465.
• [119]Mendez-Figueroa H, Lamance K, Sutton VR, Aagaard-Tillery K, Van den Veyver I: Management of Ornithine Transcarbamylase Deficiency in Pregnancy. Am J Perinatol 2010, 27:775-784.
• [120]Worthington S, Christodoulou J, Wilcken B, Peat B: Pregnancy and argininosuccinic aciduria. J Inherit Metab Dis 1996, 19:621-623.
• [121]Maestri NE, Brusilow SW, Clissold DB, Bassett SS: Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 1996, 335:855-859.
• [122]Comte B, Kasumov T, Pierce BA, Puchowicz MA, Scott ME, Dahms W, Kerr D, Nissim I, Brunengraber H: Identification of phenylbutyrylglutamine, a new metabolite of phenylbutyrate metabolism in humans. J Mass Spectrom 2002, 37:581-590.
• [123]Monneret C: Histone deacetylase inhibitors. Eur J Med Chem 2005, 40:1-13.
• [124]Tremblay GC, Qureshi IA: The biochemistry and toxicology of benzoic acid metabolism and its relationship to the elimination of waste nitrogen. Pharmacol Ther 1993, 60:63-90.
• [125]Griffith AD, Cyr DM, Egan SG, Tremblay GC: Inhibition of pyruvate carboxylase by sequestration of coenzyme A with sodium benzoate. Arch Biochem Biophys 1989, 269:201-207.
• [126]Tuchman M, Lee B, Lichter-Konecki U, Summar ML, Yudkoff M, Cederbaum SD, Kerr DS, Diaz GA, Seashore MR, Lee HS, et al.: Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab 2008, 94:397-402.
• [127]Brusilow SW, Batshaw ML: Arginine therapy of argininosuccinase deficiency. Lancet 1979, 1:124-127.
• [128]Brusilow SW: Arginine, an indispensable amino acid for patients with inborn errors of urea synthesis. J Clin Invest 1984, 74:2144-2148.
• [129]Nagasaka H, Yorifuji T, Murayama K, Kubota M, Kurokawa K, Murakami T, Kanazawa M, Takatani T, Ogawa A, Ogawa E, et al.: Effects of arginine treatment on nutrition, growth and urea cycle function in seven Japanese boys with late-onset ornithine transcarbamylase deficiency. Eur J Pediatr 2006, 165:618-624.
• [130]Keskinen P, Siitonen A, Salo M: Hereditary urea cycle diseases in Finland. Acta Paediatr 2008, 97:1412-1419.
• [131]Kim S, Paik WK, Cohen PP: Ammonia intoxication in rats: protection by N-carbamoyl-L-glutamate plus L-arginine. Proc Natl Acad Sci U S A 1972, 69:3530-3533.
• [132]Caldovic L, Morizono H, Daikhin Y, Nissim I, McCarter RJ, Yudkoff M, Tuchman M: Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate. J Pediatr 2004, 145:552-554.
• [133]Bachmann C, Colombo JP, Jaggi K: N-acetylglutamate synthetase (NAGS) deficiency: diagnosis, clinical observations and treatment. Adv Exp Med Biol 1982, 153:39-45.
• [134]Guffon N, Schiff M, Cheillan D, Wermuth B, Häberle J, Vianey-Saban C: Neonatal hyperammonemia: the N-carbamoyl-L-glutamic acid test. J Pediatr 2005, 147:260-262.
• [135]Tuchman M, Caldovic L, Daikhin Y, Horyn O, Nissim I, Nissim I, Korson M, Burton B, Yudkoff M: N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. Pediatr Res 2008, 64:213-217.
• [136]Feoli-Fonseca JC, Lambert M, Mitchell G, Melancon SB, Dallaire L, Millington DS, Qureshi IA: Chronic sodium benzoate therapy in children with inborn errors of urea synthesis: effect on carnitine metabolism and ammonia nitrogen removal. Biochem Mol Med 1996, 57:31-36.
• [137]Mayatepek E, Kurczynski TW, Hoppel CL, Gunning WT: Carnitine deficiency associated with ornithine transcarbamylase deficiency. Pediatr Neurol 1991, 7:196-199.
• [138]Ohtani Y, Ohyanagi K, Yamamoto S, Matsuda I: Secondary carnitine deficiency in hyperammonemic attacks of ornithine transcarbamylase deficiency. J Pediatr 1988, 112:409-414.
• [139]Häberle J, Lachman R: Diagnosis and treatment of OTC in females. In EMG Workshop Proceedings 2010; Lisboa. Edited by Metabolics M. Milupa Metabolics; 2010:49-59.
• [140]Morgan TM, Schlegel C, Edwards KM, Welch-Burke T, Zhu Y, Sparks R, Summar M: Vaccines are not associated with metabolic events in children with urea cycle disorders. Pediatrics 2011, 127:e1147-e1153.
• [141]Schmidt J, Kroeber S, Irouschek A, Birkholz T, Schroth M, Albrecht S: Anesthetic management of patients with ornithine transcarbamylase deficiency. Paediatr Anaesth 2006, 16:333-337.
• [142]Whitington PF, Alonso EM, Boyle JT, Molleston JP, Rosenthal P, Emond JC, Millis JM: Liver transplantation for the treatment of urea cycle disorders. J Inherit Metab Dis 1998, 21(Suppl 1):112-118.
• [143]Leonard JV, McKiernan PJ: The role of liver transplantation in urea cycle disorders. Mol Genet Metab 2004, 81(Suppl 1):S74-S78.
• [144]Morioka D, Kasahara M, Takada Y, Shirouzu Y, Taira K, Sakamoto S, Uryuhara K, Egawa H, Shimada H, Tanaka K: Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University. Liver Transpl 2005, 11:1332-1342.
• [145]Bourdeaux C, Darwish A, Jamart J, Tri TT, Janssen M, Lerut J, Otte JB, Sokal E, De Ville de Goyet J, Reding R: Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. Am J Transplant 2007, 7:440-447.
• [146]Campeau PM, Pivalizza PJ, Miller G, McBride K, Karpen S, Goss J, Lee BH: Early orthotopic liver transplantation in urea cycle defects: follow up of a developmental outcome study. Mol Genet Metab 2010, 100(Suppl 1):S84-S87.
• [147]Midgley DE, Bradlee TA, Donohoe C, Kent KP, Alonso EM: Health-related quality of life in long-term survivors of pediatric liver transplantation. Liver Transpl 2000, 6:333-339.
• [148]Bucuvalas JC, Britto M, Krug S, Ryckman FC, Atherton H, Alonso MP, Balistreri WF, Kotagal U: Health-related quality of life in pediatric liver transplant recipients: a single-center study. Liver Transpl 2003, 9:62-71.
• [149]Alonso EM, Neighbors K, Mattson C, Sweet E, Ruch-Ross H, Berry C, Sinacore J: Functional outcomes of pediatric liver transplantation. J Pediatr Gastroenterol Nutr 2003, 37:155-160.
• [150]Kawagishi N, Satoh K, Enomoto Y, Akamatsu Y, Sekiguchi S, Satoh A, Fujimori K, Takasago Y, Ito T, Ohura T, Satomi S: Improved quality of life and unchanged magnetic resonance brain imaging after living donor liver transplantation for late-onset ornithine transcarbamylase deficiency: report of a case. Surg Today 2005, 35:1087-1091.
• [151]Busuttil AA, Goss JA, Seu P, Dulkanchainun TS, Yanni GS, McDiarmid SV, Busuttil RW: The role of orthotopic liver transplantation in the treatment of ornithine transcarbamylase deficiency. Liver Transpl Surg 1998, 4:350-354.
• [152]Fletcher JM, Couper R, Moore D, Coxon R, Dorney S: Liver transplantation for citrullinaemia improves intellectual function. J Inherit Metab Dis 1999, 22:581-586.
• [153]Santos Silva E, Martins E, Cardoso ML, Barbot C, Vilarinho L, Medina M: Liver transplantation in a case of argininaemia. J Inherit Metab Dis 2001, 24:885-887.
• [154]Ensenauer R, Tuchman M, El-Youssef M, Kotagal S, Ishitani MB, Matern D, Babovic-Vuksanovic D: Management and outcome of neonatal-onset ornithine transcarbamylase deficiency following liver transplantation at 60 days of life. Mol Genet Metab 2005, 84:363-366.
• [155]McBride KL, Miller G, Carter S, Karpen S, Goss J, Lee B: Developmental outcomes with early orthotopic liver transplantation for infants with neonatal-onset urea cycle defects and a female patient with late-onset ornithine transcarbamylase deficiency. Pediatrics 2004, 114:e523-e526.
• [156]Newnham T, Hardikar W, Allen K, Wellard RM, Hamilton C, Angus P, Jones R, Boneh A: Liver transplantation for argininosuccinic aciduria: clinical, biochemical, and metabolic outcome. Liver Transpl 2008, 14:41-45.
• [157]Stevenson T, Millan MT, Wayman K, Berquist WE, Sarwal M, Johnston EE, Esquivel CO, Enns GM: Long-term outcome following pediatric liver transplantation for metabolic disorders. Pediatr Transplant 2009, 14:268-275.
• [158]Noujaim HM, Mayer DA, Buckles JA, Beath SV, Kelly DA, McKiernan PJ, Mirza DF, de Ville De Goyet J: Techniques for and outcome of liver transplantation in neonates and infants weighing up to 5 kilograms. J Pediatr Surg 2002, 37:159-164.
• [159]Sundaram SS, Alonso EM, Whitington PF: Liver transplantation in neonates. Liver Transpl 2003, 9:783-788.
• [160]Bachmann C: Ornithine carbamoyl transferase deficiency: findings, models and problems. J Inherit Metab Dis 1992, 15:578-591.
• [161]Hashikura Y, Ichida T, Umeshita K, Kawasaki S, Mizokami M, Mochida S, Yanaga K, Monden M, Kiyosawa K: Donor complications associated with living donor liver transplantation in Japan. Transplantation 2009, 88:110-114.
• [162]Nagasaka H, Yorifuji T, Egawa H, Kikuta H, Tanaka K, Kobayashi K: Successful living-donor liver transplantation from an asymptomatic carrier mother in ornithine transcarbamylase deficiency. J Pediatr 2001, 138:432-434.
• [163]Morioka D, Takada Y, Kasahara M, Ito T, Uryuhara K, Ogawa K, Egawa H, Tanaka K: Living donor liver transplantation for noncirrhotic inheritable metabolic liver diseases: impact of the use of heterozygous donors. Transplantation 2005, 80:623-628.
• [164]Wilcox G, Strauss BJ, Francis DE, Upton H, Boneh A: Body composition in young adults with inborn errors of protein metabolism–a pilot study. J Inherit Metab Dis 2005, 28:613-626.
• [165]Lee PJ: Hyperammonaemia in adolescence and adulthood. In Pathophysiology and management of hyperammonaemia. Edited by Bachmann C, Häberle J, Leonard J. SPS Verlagsgesellschaft, Heilbronn; 2006:93-99.
• [166]Barsotti RJ: Measurement of ammonia in blood. J Pediatr 2001, 138:S11-S19. discussion S19-20
• [167]de Keijzer MH, Jakobs BS, Brandts RW, Hofs MT, Trijbels FJ, Smeitink JA: Rapid and reliable measurement of highly elevated blood ammonia concentrations in children. Eur J Clin Chem Clin Biochem 1997, 35:853-854.
• [168]Maestri NE, McGowan KD, Brusilow SW: Plasma glutamine concentration: a guide in the management of urea cycle disorders. J Pediatr 1992, 121:259-261.
• [169]Brusilow SW: Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res 1991, 29:147-150.
• [170]Bachmann C: Interpretation of plasma amino acids in the follow-up of patients: the impact of compartmentation. J Inherit Metab Dis 2008, 31:7-20.
• [171]Duran M: Amino Acids. In Laboratory Guide to the Methods in Biochemical Genetics. Edited by Blau N, Duran M, Gibson KM. Springer, Berlin Heidelberg; 2008:53-89.
• [172]MacArthur RB, Altincatal A, Tuchman M: Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers. Mol Genet Metab 2004, 81(Suppl 1):S67-S73.
• [173]Gropman A: Brain imaging in urea cycle disorders. Mol Genet Metab 2010, 100(Suppl 1):S20-S30.
• [174]Gropman AL, Fricke ST, Seltzer RR, Hailu A, Adeyemo A, Sawyer A, van Meter J, Gaillard WD, McCarter R, Tuchman M, Batshaw M: 1H MRS identifies symptomatic and asymptomatic subjects with partial ornithine transcarbamylase deficiency. Mol Genet Metab 2008, 95:21-30.
• [175]Gropman AL, Gertz B, Shattuck K, Kahn IL, Seltzer R, Krivitsky L, Van Meter J: Diffusion tensor imaging detects areas of abnormal white matter microstructure in patients with partial ornithine transcarbamylase deficiency. Am J Neuroradiol 2010, 31:1719-1723.
• [176]Takanashi J, Barkovich AJ, Cheng SF, Weisiger K, Zlatunich CO, Mudge C, Rosenthal P, Tuchman M, Packman S: Brain MR imaging in neonatal hyperammonemic encephalopathy resulting from proximal urea cycle disorders. Am J Neuroradiol 2003, 24:1184-1187.
• [177]Majoie CB, Mourmans JM, Akkerman EM, Duran M, Poll-The BT: Neonatal citrullinemia: comparison of conventional MR, diffusion-weighted, and diffusion tensor findings. Am J Neuroradiol 2004, 25:32-35.
• [178]Connelly A, Cross JH, Gadian DG, Hunter JV, Kirkham FJ, Leonard JV: Magnetic resonance spectroscopy shows increased brain glutamine in ornithine carbamoyl transferase deficiency. Pediatr Res 1993, 33:77-81.
• [179]Choi CG, Yoo HW: Localized proton MR spectroscopy in infants with urea cycle defect. Am J Neuroradiol 2001, 22:834-837.
• [180]Gropman AL, Batshaw ML: Cognitive outcome in urea cycle disorders. Mol Genet Metab 2004, 81(Suppl 1):S58-S62.
• [181]Drogari E, Leonard JV: Late onset ornithine carbamoyl transferase deficiency in males. Arch Dis Child 1988, 63:1363-1367.
• [182]Hatzmann J, Heymans HS, Ferrer-i-Carbonell A, van Praag BM, Grootenhuis MA: Hidden consequences of success in pediatrics: parental health-related quality of life–results from the Care Project. Pediatrics 2008, 122:e1030-e1038.
• [183]Cederbaum JA, LeMons C, Rosen M, Ahrens M, Vonachen S, Cederbaum SD: Psychosocial issues and coping strategies in families affected by urea cycle disorders. J Pediatr 2001, 138:S72-S80.
• [184]Bosch AM, Grootenhuis MA, Bakker HD, Heijmans HS, Wijburg FA, Last BF: Living with classical galactosemia: health-related quality of life consequences. Pediatrics 2004, 113:e423-e428.
• [185]Brumm VL, Bilder D, Waisbren SE: Psychiatric symptoms and disorders in phenylketonuria. Mol Genet Metab 2010, 99(Suppl 1):S59-S63.
• [186]Feillet F, MacDonald A, Hartung Perron D, Burton B: Outcomes beyond phenylalanine: an international perspective. Mol Genet Metab 2010, 99(Suppl 1):S79-S85.
• [187]Varni JW, Burwinkle TM, Lane MM: Health-related quality of life measurement in pediatric clinical practice: an appraisal and precept for future research and application. Health Qual Life Outcomes 2005, 3:34.
• [188]Nordenstrom A, Halldin M, Hallberg B, Alm J: A trial with N-carbamylglutamate may not detect all patients with NAGS deficiency and neonatal onset. J Inherit Metab Dis 2007, 30:400.
• [189]Ah Mew N, Daikhin E, Payan I, Nissim I, Nissim I, Yudkoff M, Tuchman M: N-carbamylglutamate increases ureagenesis in patients with CPSI deficiency (abstract). Mol Genet Metab 2010, 99:207.
• [190]Williams M, Huijmans JG, van Diggelen OP, van der Louw EJTM, De Klerk JBC, Häberle J: Carbamoylphosphate synthase I (CPS 1) deficiency: treatment with carglumic acid (Carbaglu) (abstract). J Inherit Metab Dis 2010, 33:S118.
• [191]Caldovic L, Morizono H, Panglao MG, Cheng SF, Packman S, Tuchman M: Null mutations in the N-acetylglutamate synthase gene associated with acute neonatal disease and hyperammonemia. Hum Genet 2003, 112:364-368.
• [192]Ihara K, Miyako K, Ishimura M, Kuromaru R, Wang HY, Yasuda K, Hara T: A case of hyperinsulinism/hyperammonaemia syndrome with reduced carbamoyl-phosphate synthetase-1 activity in liver: a pitfall in enzymatic diagnosis for hyperammonaemia. J Inherit Metab Dis 2005, 28:681-687.
• [193]Häberle J: Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency. Ther Clin Risk Manag 2011, 7:1-6.
• [194]Gessler P, Buchal P, Schwenk HU, Wermuth B: Favourable long-term outcome after immediate treatment of neonatal hyperammonemia due to N-acetylglutamate synthase deficiency. Eur J Pediatr 2010, 169:197-199.
• [195]Belanger-Quintana A, Martinez-Pardo M, Garcia MJ, Wermuth B, Torres J, Pallares E, Ugarte M: Hyperammonaemia as a cause of psychosis in an adolescent. Eur J Pediatr 2003, 162:773-775.
• [196]Guffon N, Gessler P, Galloway P, Martinez-Pardo M, Meli C, Mulder M, Nordenstrom A, Plecko B, Scheible D, Valayannopoulos V, Häberle J: Treatment of NAGS deficiency: retrospective data on 23 patients treated with carglumic acid over 16 years (abstract). Mol Genet Metab 2011, 102:286-287.
• [197]Tuchman M: The clinical, biochemical, and molecular spectrum of ornithine transcarbamylase deficiency. J Lab Clin Med 1992, 120:836-850.
• [198]Numata S, Koda Y, Ihara K, Sawada T, Okano Y, Matsuura T, Endo F, Yoo HW, Arranz JA, Rubio V, et al.: Mutant alleles associated with late-onset ornithine transcarbamylase deficiency in male patients have recurrently arisen and have been retained in some populations. J Hum Genet 2010, 55:18-22.
• [199]Numata S, Harada E, Maeno Y, Ueki I, Watanabe Y, Fujii C, Yanagawa T, Takenaka S, Inoue T, Inoue S, et al.: Paternal transmission and slow elimination of mutant alleles associated with late-onset ornithine transcarbamylase deficiency in male patients. J Hum Genet 2008, 53:10-17.
• [200]Shchelochkov OA, Li FY, Geraghty MT, Gallagher RC, Van Hove JL, Lichter-Konecki U, Fernhoff PM, Copeland S, Reimschisel T, Cederbaum S, et al.: High-frequency detection of deletions and variable rearrangements at the ornithine transcarbamylase (OTC) locus by oligonucleotide array CGH. Mol Genet Metab 2009, 96:97-105.
• [201]Hauser ER, Finkelstein JE, Valle D, Brusilow SW: Allopurinol-induced orotidinuria. A test for mutations at the ornithine carbamoyltransferase locus in women. N Engl J Med 1990, 322:1641-1645.
• [202]Maestri NE, Lord C, Glynn M, Bale A, Brusilow SW: The phenotype of ostensibly healthy women who are carriers for ornithine transcarbamylase deficiency. Medicine (Baltimore) 1998, 77:389-397.
• [203]Grunewald S, Fairbanks L, Genet S, Cranston T, Husing J, Leonard JV, Champion MP: How reliable is the allopurinol load in detecting carriers for ornithine transcarbamylase deficiency? J Inherit Metab Dis 2004, 27:179-186.
• [204]Tuchman M: Allopurinol-induced orotidinuria. N Engl J Med 1990, 323:1352-1353.
• [205]Potter M, Hammond JW, Sim KG, Green AK, Wilcken B: Ornithine carbamoyltransferase deficiency: improved sensitivity of testing for protein tolerance in the diagnosis of heterozygotes. J Inherit Metab Dis 2001, 24:5-14.
• [206]Engel K, Höhne W, Häberle J: Mutations and polymorphisms in the human argininosuccinate synthetase (ASS1) gene. Hum Mutat 2009, 30:300-307.
• [207]Kleijer WJ, Thoomes R, Galjaard H, Wendel U, Fowler B: First-trimester (chorion biopsy) diagnosis of citrullinaemia and methylmalonicaciduria. Lancet 1984, 2:1340.
• [208]Berning C, Bieger I, Pauli S, Vermeulen T, Vogl T, Rummel T, Hohne W, Koch HG, Rolinski B, Gempel K, Häberle J: Investigation of citrullinemia type I variants by in vitro expression studies. Hum Mutat 2008, 29:1222-1227.
• [209]Enns GM, O’Brien WE, Kobayashi K, Shinzawa H, Pellegrino JE: Postpartum “psychosis” in mild argininosuccinate synthetase deficiency. Obstet Gynecol 2005, 105:1244-1246.
• [210]Engel K, Vuissoz JM, Eggimann S, Groux M, Berning C, Hu L, Klaus V, Moeslinger D, Mercimek-Mahmutoglu S, Stockler S, et al.: Bacterial expression of mutant argininosuccinate lyase reveals imperfect correlation of in-vitro enzyme activity with clinical phenotype in argininosuccinic aciduria. J Inherit Metab Dis 2011, 35:133-140.
• [211]Trevisson E, Burlina A, Doimo M, Pertegato V, Casarin A, Cesaro L, Navas P, Basso G, Sartori G, Salviati L: Functional complementation in yeast allows molecular characterization of missense argininosuccinate lyase mutations. J Biol Chem 2009, 284:28926-28934.
• [212]Kölker S, Sauer SW, Surtees RA, Leonard JV: The aetiology of neurological complications of organic acidaemias--a role for the blood–brain barrier. J Inherit Metab Dis 2006, 29:701-704. discussion 705–706
• [213]van Spronsen FJ, Reijngoud DJ, Verhoeven NM, Soorani-Lunsing RJ, Jakobs C, Sijens PE: High cerebral guanidinoacetate and variable creatine concentrations in argininosuccinate synthetase and lyase deficiency: implications for treatment? Mol Genet Metab 2006, 89:274-276.
• [214]Erez A, Nagamani SC, Shchelochkov OA, Premkumar MH, Campeau PM, Chen Y, Garg HK, Li L, Mian A, Bertin TK, et al.: Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat Med 2011, 17:1619-1626.
• [215]Zimmermann A, Bachmann C, Baumgartner R: Severe liver fibrosis in argininosuccinic aciduria. Arch Pathol Lab Med 1986, 110:136-140.
• [216]Jordá A, Rubio V, Portolés M, Vilas J, Garcia-Pino J: A new case of arginase deficiency in a Spanish male. J Inherit Metab Dis 1986, 9:393-397.
• [217]Gomes Martins E, Santos Silva E, Vilarinho S, Saudubray JM, Vilarinho L: Neonatal cholestasis: an uncommon presentation of hyperargininemia. J Inherit Metab Dis 2011.
• [218]Scholl-Bürgi S, Sigl SB, Häberle J, Haberlandt E, Rostasy K, Ertl C, Eichinger-Ottl U, Heinz-Erian P, Karall D: Amino acids in CSF and plasma in hyperammonaemic coma due to arginase1 deficiency. J Inherit Metab Dis 2008, 31(Suppl 2):S323-S328.
• [219]Scaglia F, Lee B: Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency. Am J Med Genet C Semin Med Genet 2006, 142C:113-120.
• [220]Cederbaum SD, Moedjono SJ, Shaw KN, Carter M, Naylor E, Walzer M: Treatment of hyperargininaemia due to arginase deficiency with a chemically defined diet. J Inherit Metab Dis 1982, 5:95-99.
• [221]Ash DE, Scolnick LR, Kanyo ZF, Vockley JG, Cederbaum SD, Christianson DW: Molecular basis of hyperargininemia: structure-function consequences of mutations in human liver arginase. Mol Genet Metab 1998, 64:243-249.
• [222]Bachmann C, Colombo JP: Orotic acid in urine and hyperammonemia. Adv Exp Med Biol 1982, 153:313-319.
• [223]Brosnan JT, Brosnan ME: Creatine metabolism and the urea cycle. Mol Genet Metab 2010, 100(Suppl 1):S49-S52.
• [224]Qureshi IA, Letarte J, Ouellet R, Batshaw ML, Brusilow S: Treatment of hyperargininemia with sodium benzoate and arginine-restricted diet. J Pediatr 1984, 104:473-476.
• [225]Debray FG, Lambert M, Lemieux B, Soucy JF, Drouin R, Fenyves D, Dube J, Maranda B, Laframboise R, Mitchell GA: Phenotypic variability among patients with hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome homozygous for the delF188 mutation in SLC25A15. J Med Genet 2008, 45:759-764.
• [226]Palmieri F: Diseases caused by defects of mitochondrial carriers: a review. Biochim Biophys Acta 2008, 1777:564-578.
• [227]Shih VE, Mandell R, Herzfeld A: Defective ornithine metabolism in cultured skin fibroblasts from patients with the syndrome of hyperornithinemia, hyperammonemia and homocitrullinuria. Clin Chim Acta 1982, 118:149-157.
• [228]Camacho JA, Obie C, Biery B, Goodman BK, Hu CA, Almashanu S, Steel G, Casey R, Lambert M, Mitchell GA, Valle D: Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter. Nat Genet 1999, 22:151-158.
• [229]Dionisi Vici C, Bachmann C, Gambarara M, Colombo JP, Sabetta G: Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome: low creatine excretion and effect of citrulline, arginine, or ornithine supplement. Pediatr Res 1987, 22:364-367.
• [230]Morini C, Capozzi P, Boenzi S, Rizzo C, Santorelli FM, Dionisi-Vici C: Retinal degeneration. Ophthalmology 2009, 116:1593.
• [231]Yudkoff M, Ah Mew N, Daikhin Y, Horyn O, Nissim I, Nissim I, Payan I, Tuchman M: Measuring in vivo ureagenesis with stable isotopes. Mol Genet Metab 2010, 100(Suppl 1):S37-S41.
• [232]Yudkoff M, Daikhin Y, Nissim I, Jawad A, Wilson J, Batshaw M: In vivo nitrogen metabolism in ornithine transcarbamylase deficiency. J Clin Invest 1996, 98:2167-2173.
• [233]Quental R, Azevedo L, Rubio V, Diogo L, Amorim A: Molecular mechanisms underlying large genomic deletions in ornithine transcarbamylase (OTC) gene. Clin Genet 2009, 75:457-464.
• [234]Consortium GP: A map of human genome variation from population-scale sequencing. Nature 2010, 467:1061-1073.
• [235]Arranz JA, Riudor E, Marco-Marin C, Rubio V: Estimation of the total number of disease-causing mutations in ornithine transcarbamylase (OTC) deficiency. Value of the OTC structure in predicting a mutation pathogenic potential. J Inherit Metab Dis 2007, 30:217-226.
• [236]Laskowski RA, Thornton JM: Understanding the molecular machinery of genetics through 3D structures. Nat Rev Genet 2008, 9:141-151.
• [237]Pekkala S, Martinez AI, Barcelona B, Gallego J, Bendala E, Yefimenko I, Rubio V, Cervera J: Structural insight on the control of urea synthesis: identification of the binding site for N-acetyl-L-glutamate, the essential allosteric activator of mitochondrial carbamoyl phosphate synthetase. Biochem J 2009, 424:211-220.
• [238]Pekkala S, Martinez AI, Barcelona B, Yefimenko I, Finckh U, Rubio V, Cervera J: Understanding carbamoyl-phosphate synthetase I (CPS1) deficiency by using expression studies and structure-based analysis. Hum Mutat 2010, 31:801-808.
• [239]Pey AL, Ying M, Cremades N, Velazquez-Campoy A, Scherer T, Thöny B, Sancho J, Martinez A: Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J Clin Invest 2008, 118:2858-2867.
• [240]Deignan JL, Cederbaum SD, Grody WW: Contrasting features of urea cycle disorders in human patients and knockout mouse models. Mol Genet Metab 2008, 93:7-14.
• [241]Braissant O: Current concepts in the pathogenesis of urea cycle disorders. Mol Genet Metab 2010, 100(Suppl 1):S3-S12.
• [242]Braissant O, Henry H, Villard AM, Zurich MG, Loup M, Eilers B, Parlascino G, Matter E, Boulat O, Honegger P, Bachmann C: Ammonium-induced impairment of axonal growth is prevented through glial creatine. J Neurosci 2002, 22:9810-9820.
• [243]Bachmann C: Mechanisms of hyperammonemia. Clin Chem Lab Med 2002, 40:653-662.
• [244]Hermenegildo C, Marcaida G, Montoliu C, Grisolia S, Minana MD, Felipo V: NMDA receptor antagonists prevent acute ammonia toxicity in mice. Neurochem Res 1996, 21:1237-1244.
• [245]Felipo V, Butterworth RF: Mitochondrial dysfunction in acute hyperammonemia. Neurochem Int 2002, 40:487-491.
• [246]Jalan R, Rose C: Hypothermia in acute liver failure. Metab Brain Dis 2004, 19:215-221.
• [247]Rabinstein AA: Treatment of brain edema in acute liver failure. Curr Treat Options Neurol 2010, 12:129-141.
• [248]Whitelaw A, Bridges S, Leaf A, Evans D: Emergency treatment of neonatal hyperammonaemic coma with mild systemic hypothermia. Lancet 2001, 358:36-38.
• [249]Dhawan A, Mitry RR, Hughes RD: Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis 2006, 29:431-435.
• [250]Enns GM, Millan MT: Cell-based therapies for metabolic liver disease. Mol Genet Metab 2008, 95:3-10.
• [251]Meyburg J, Das AM, Hoerster F, Lindner M, Kriegbaum H, Engelmann G, Schmidt J, Ott M, Pettenazzo A, Luecke T, et al.: One liver for four children: first clinical series of liver cell transplantation for severe neonatal urea cycle defects. Transplantation 2009, 87:636-641.
• [252]Meyburg J, Hoffmann GF: Liver, liver cell and stem cell transplantation for the treatment of urea cycle defects. Mol Genet Metab 2010, 100(Suppl 1):S77-S83.
• [253]Brunetti-Pierri N, Clarke C, Mane V, Palmer DJ, Lanpher B, Sun Q, O’Brien W, Lee B: Phenotypic correction of ornithine transcarbamylase deficiency using low dose helper-dependent adenoviral vectors. J Gene Med 2008, 10:890-896.
• [254]Patejunas G, Lee B, Dennis JA, Healy PJ, Reeds PJ, Yu H, Frazer M, Mull B, Warman AW, Beaudet AL, O’Brien WE: Evaluation of gene therapy for citrullinaemia using murine and bovine models. J Inherit Metab Dis 1998, 21(Suppl 1):138-150.
• [255]Lee B, Dennis JA, Healy PJ, Mull B, Pastore L, Yu H, Aguilar-Cordova E, O’Brien W, Reeds P, Beaudet AL: Hepatocyte gene therapy in a large animal: a neonatal bovine model of citrullinemia. Proc Natl Acad Sci U S A 1999, 96:3981-3986.
• [256]Moscioni D, Morizono H, McCarter RJ, Stern A, Cabrera-Luque J, Hoang A, Sanmiguel J, Wu D, Bell P, Gao GP, et al.: Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors. Mol Ther 2006, 14:25-33.
• [257]Cunningham SC, Spinoulas A, Carpenter KH, Wilcken B, Kuchel PW, Alexander IE: AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice. Mol Ther 2009, 17:1340-1346.
• [258]Cunningham SC, Kok CY, Dane AP, Carpenter K, Kizana E, Kuchel PW, Alexander IE: Induction and prevention of severe hyperammonemia in the spfash mouse model of ornithine transcarbamylase deficiency using shRNA and rAAV-mediated gene delivery. Mol Ther 2011, 19:854-859.
• [259]Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ, Furth EE, Propert KJ, Robinson MB, Magosin S, et al.: A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002, 13:163-175.
• [260]Wilson JM: Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 2009, 96:151-157.
• [261]Terheggen HG, Lowenthal A, Lavinha F, Colombo JP, Rogers S: Unsuccessful trial of gene replacement in arginase deficiency. Z Kinderheilkd 1975, 119:1-3.
• [262]Sakiyama T, Nakabayashi H, Shimizu H, Kondo W, Kodama S, Kitagawa T: A successful trial of enzyme replacement therapy in a case of argininemia. Tohoku J Exp Med 1984, 142:239-248.
• [263]Mizutani N, Hayakawa C, Maehara M, Watanabe K: Enzyme replacement therapy in a patient with hyperargininemia. Tohoku J Exp Med 1987, 151:301-307.